KRM Ayurveda
Disclaimer: This content is provided strictly for educational and informational purposes. The securities or investments mentioned are not to be considered as investment advice or recommendations.
KRM Ayurveda IPO is scheduled to open for subscription on January 21, 2026, and will close on January 23, 2026. This IPO is a book-built issue, through which the company aims to raise approximately ₹77 crore. The issue consists entirely of a fresh equity issue worth ₹77 crore, with equity shares having a face value of ₹10 each.
The price band for the KRM Ayurveda IPO has been fixed between ₹128 and ₹135 per share. The allocation is divided as follows: 35% for retail investors, 50% for Qualified Institutional Buyers (QIBs), and 15% for High Net-worth Individuals (HNIs). The shares are proposed to be listed on the NSE SME platform on January 29, 2026, while the IPO allotment is expected on January 27, 2026.
From a financial perspective, the company has shown consistent growth. Revenue increased to ₹76.95 crore in FY2025, compared to ₹67.57 crore in FY2024. Profit after tax also rose significantly to ₹12.10 crore in FY2025, up from ₹3.41 crore in the previous year. Based on its improving financial performance, the IPO may be considered by investors with a long-term investment horizon.
About KRM Ayurveda IPO
KRM Ayurveda Ltd was founded on September 3, 2019, and specializes in the manufacturing of Ayurvedic products, herbal remedies, medicines, supplements, and wellness or skincare items.
The company operates a network of hospitals and clinics across India and also provides telemedicine services and international sales. Currently, KRM Ayurveda runs 6 hospitals and 5 clinics at various locations, offering services such as in-patient and out-patient care, Panchakarma therapies, specialized clinics, medicinal sales, and diet & lifestyle counseling.
Strengths:
Highly skilled Ayurvedic doctors and trained therapists ensure effective and quality treatment.
Established and trusted brand with a loyal customer base and repeat clientele.
KRM Ayurveda IPO Details
IPO Open Date | January 21, 2026 |
IPO Close Date | January 23, 2026 |
Face Value | ₹10 Per Equity Share |
IPO Price Band | ₹128 to ₹135 Per Share |
Issue Size | Approx ₹77 Crores |
Fresh Issue | Approx ₹77 Crores |
Issue Type | Book Build Issue |
IPO Listing | NSE SME |
DRHP Draft Prospectus | https://nsearchives.nseindia.com/emerge/corporates/content/Registration_22092025152123_DRHP_KRM.pdf |
RHP Draft Prospectus | https://www.krmayurvedaindia.com/documents/DRHP_KRM_Ayurveda_Limited.pdf |
KRM Ayurveda IPO Market Lot
The KRM Ayurveda IPO minimum market lot is 2,000 shares with ₹2,70,000 application amount.
Application | Lot Size | Shares | Amount |
Retail Minimum | 2 | 2,000 | ₹2,70,000 |
Retail Maximum | 2 | 2,000 | ₹2,70,000 |
S-HNI Minimum | 3 | 3,000 | ₹4,05,000 |
S-HNI Maximum | 7 | 7,000 | ₹9,45,000 |
B-HNI Minimum | 8 | 8,000 | ₹10,80,000 |
Objects of the Issue & Utilisation of proceeds
Purpose | Crores |
Capital Expenditure for Construction and Development of Telemedicine Operational Facilities | ₹13.67 |
Purchase of CRM Software and Hardware Infrastructure | ₹1.42 |
Human Resources | ₹5.44 |
Repayment/Prepayment of loan | ₹12.50 |
Working Capital Requirement | ₹18.00 |
General Corporate Purpose | ₹- |
KRM Ayurveda IPO Company Financial Report
Amount ₹ in Crores
Period Ended | Revenue | Expense | PAT | Assets |
2023 | ₹89.38 | ₹79.29 | ₹7.60 | ₹39.48 |
2024 | ₹67.57 | ₹62.85 | ₹3.41 | ₹43.91 |
2025 | ₹76.95 | ₹60.61 | ₹12.10 | ₹66.79 |
Sep 2025 | ₹48.65 | ₹37.65 | ₹8.14 | ₹78.12 |
Peer Group Comparison
Company | EPS | PE Ratio | RoNW % | NAV | Income |
Jeena Sikho Lifecare Ltd. | 8.86 | 76.58 | 31.28% | 142.24 | 110.10 Cr. |
Vaidya Sane Ayurved Laboratories Ltd | 3.07 | 93.20 | 5.12% | 59.85 | 3.22 Cr. |
KRM Ayurveda IPO Valuation – FY2025
Check KRM Ayurveda IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
KPI | Values |
ROE: | 67.86% |
ROCE: | 43.33% |
EBITDA Margin: | 24.96% |
PAT Margin: | 15.80% |
Debt to equity ratio: | 1.31 |
Earning Per Share (EPS): | ₹8.06 (Basic) |
Price/Earning P/E Ratio: | N/A |
Return on Net Worth (RoNW): | 67.86% |
Net Asset Value (NAV): | ₹1,602.40 |